Published Sep 19, 2026
MacroGenics (MGNX): Plant Sale Funds a Leaner Antibody Pipeline Bet
In-depth research on MGNX covering the business overview, key financial moves, risk frame, and the bottom-line on what changed since the last report.
3,956 words18 min read
Read report